Weizmann Institute of Science

Born in Israel, Prof. Yosef Yarden received his BSc in biological and geological sciences from the Hebrew University of Jerusalem (1980), and a PhD in molecular biology from the Weizmann Institute of Science (1985). His postdoctoral training was undertaken at Genentech, Inc., in San Francisco and at the Massachusetts Institute of Technology. In 1988, he joined the Weizmann Institute of Science’s faculty. At the Institute, he has served as Dean of the Faculty of Biology (1997-1999), Vice President for Academic Affairs (1999-2001), the first Director of the MD Moross Institute for Cancer Research (1999-2001), and Dean of the Feinberg Graduate School (2001-2007). He is the new director of the Dwek Institute for Cancer Therapy Research of the Moross Integrated Cancer Center and became the head of the Department of Biological Regulation in June, 2017. He is the Harold and Zelda Goldenberg Professor of Molecular Cell Biology. From 2011 till 2014 Prof. Yarden served as President of the Federations of Israeli Societies of Experimental Biology (FISEB/ILANIT). Among his many honors and awards are the Israel Prize in Life Sciences (2017), the EMET Prize in Biochemistry (2007), the 43rd Leoplod Griffuel Award of Fondation ARC pour la Recherche sur le Cancer (2015), the Susan G. Komen for the Cure® Brinker Award for Scientific Distinction in Basic Research (2012), the Ernst W. Bertner Memorial Award of the University of Texas’ MD Anderson Cancer Center (2010), the 2008 Hamilton Fairly Award of the European Societies of Clinical Oncology (ESMO), the MERIT award of the U.S. National Cancer Institute (2005), the TEVA Founders Prize (2004), and the Michael Bruno Prize of the Yad Hanadiv (Rothschild) Fund (2000). He was elected to the Israel Academy of Science and Humanities in 2007.

Hospital Beaujon

Dr. Ailton Sepulveda é cirurgião pós-graduado em cirurgia Hepatobiliar e em Transplante de Fígado pela Faculdade de Medicina da Universidade de São Paulo com especialização pela Universidade Paris V. Mestre em Ciência e Tecnologia pela Universidade Paris VI. Radicado na França há mais de 10 anos onde integrou a equipe do Pr. Olivier Soubrane. Atualmente ele é cirurgião titular do Hospital Beaujon implicado na cirurgia hepática laparoscópica, transplante de fígado e cirurgia minimamente invasiva.

Palestras:

• Room: ENCONTRO DE EX-RESIDENTES DO A.C.CAMARGO CANCER CENTER
• Room: TUMORES DO APARELHO DIGESTIVO ALTO :: LOCAL - R30/31

Hospital Britanico - Buenos Aires

Jefe del Servicio de Urologia Hospital Británico de Buenos Aires Jefe del Servicio del Hospital Universitario Austral Profesor Adjunto a cargo de la Cátedra de Urologia de la Universidad Austral Profesor Adjunto de la Universidad Católica Argentina

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Associate Professor of Pathology University of Florida Medical Center

Dra. Alessandra Nascimento, MD is a board certified pathologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts and Florida. She is affiliated with Brigham and Women's Hospital and is an Assistant Professor of Pathology at Brigham and Women's Hospital.

Palestras:

• Room: SARCOMAS E TUMORES ÓSSEOS :: LOCAL - R39/40

MD Anderson Cancer Center

Dr. Anil Sood is a Professor and the Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology. He is also the co-director of the Center for RNA Interference and Non-Coding RNA at the MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program.

Palestras:

• Room: TUMORES GINECOLÓGICOS :: LOCAL - BALLROOM 3

UCLA

Brian Shuch, MD was recently recruited to UCLA as the Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research. Previously Dr. Shuch was at Yale University where was an Associate Professor of Urology and Diagnostic Radiology and Director of the Genitourinary Cancer Genetics and Prevention Program as well as the Genitourinary Biospecimen Repository. He completed his urology training at UCLA followed by a Urologic Oncology Fellowship at the National Cancer Institute. He is an accomplished surgeon (open/laparoscopic/robotic/and percutaneous) and clinical/translational researcher. He serves in leadership positions within various kidney cancer research organizations such as SWOG, the SUO Clinical Trial Consortium, and the Kidney Cancer Association. He is recognized as an expert in the genetics of kidney cancer and runs an NIH-funded laboratory with 100 peer reviewed publications including primary research published in prestigious journals such as Nature Genetics, Proceedings of the National Academy of Sciences, and Clinical Cancer Research.

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Internacional Kidney Cancer Coalition

Dr. Bryan Lewis has led the advocacy efforts for KCAN – the Kidney Cancer Action Network – www.kcan.org. As a kidney cancer survivor, he has been an active legislative advocate and policy spokesman for the kidney cancer community in Washington, D.C. devoting most of his efforts to policy advocacy in the United States Congress & regulatory agencies

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Institut Curie

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 140+ peer-reviewed papers in international journals.

Palestras:

• Room: INSTITUT CURIE

LARCG / Hospital Pasteur Montevideo

Urologist at Pasteur Hospital, Montevideo, Uruguay Urologist at CASMU IAMPP (Private Health Institution), Montevideo, Uruguay. Consultant since 2016. Residency in Urology, Universidad de la Republica, Facultad de Medicina, Hospital de Clínicas. Montevideo. Uruguay

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Princess Margaret Cancer Centre

Dr. Eitan Amir is a Medical Oncologist at Princess Margaret Cancer Centre in Toronto and an Associate Professor in the Department of Medicine at the University of Toronto. He also serves as the Cancer Care Ontario Systemic Therapy Lead for Toronto Central South and as the Vice-Chair of the Cancer Research Ethics Board at University Health Network.

Palestras:

• Room: TUMORES DE MAMA :: LOCAL - SALA GALERIA

Internacional kidney Cancer coalition / MD Anderson Cancer Center

Dr. Eric Jonasch , is Associate Professor in the Department of Genitourinary (GU) Medical Oncology in the Division of Cancer Medicine at The University of Texas M. D. Anderson Cancer Center. He completed his medical education at McGill University in Montreal, Canada. Dr. Jonasch’s research interests lie in renal cell carcinoma, pathology, carcinogenesis, tissue microarray, molecular biology and protein phosphorylation. He is board certified in medical oncology, hematology and internal medicine by the American Board of Internal Medicine and oncology and medicine by the Royal College of Physicians & Surgeons of Canada.

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Inst. Nacional de Ciencias Médicas y Nutrición Salvador Zubirán-Mexico

Since July 2007, Dr. Rodriguez-Covarrubias serves as attending urologist at the Department of Urology at Instituto Nacional de Nutricion Salvador Zubiran in Mexico City, where he completed his general surgery and urology residency. He has 1-year fellowship training in Laparoscopy and Urological Oncology at the Department of Urology at Henri Mondor University Hospital in Créteil, France under the mentorship of Professor Claude C. Abbou. Since September 2009, Dr. Rodriguez-Covarrubias has been appointed as a Researcher for the National Researchers System at the Science and Technology National Council (CONACYT) in Mexico. Dr. Rodriguez-Covarrubias has authored more than 50 papers published in peer-reviewed journals including Lancet, The Journal of Urology, Urology and BJU International. His main areas of interest and research include Urologic Oncology, Laparoscopy, Kidney Transplants and Urinary Tract Infections. Currently, Dr. Rodriguez-Covarrubias serves as President of the Mexican Association of Urologic Oncology and as Coordinator of the Uro-Oncology Chapter of the Mexican Society of Urology.

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL

Marien Hospital Bottrop

Dr. Hans-Christian Kolberg - Since 2005 Dr. Kolberg is head of department for gynecology and obstetrics at the Marienhospital Bottrop, an academic teaching hospital for the University of Essen. He is also leading the multidisciplinary breast cancer center and gynecologic cancer center at his institution. Before 2005 he was a senior consultant and director of breast services at the University Hospital of Schleswig-Holstein, Campus Lübeck, where he lead the breast cancer center to the first accreditation by the EUSOMA in Germany in 2004. Besides his clinical work he also principal investigator for numerous clinical trials mainly regarding breast cancer and one of the spokesmen of the German Network of Certified Breast Cancer Centers. His scientific focus is the de-escalation of local and systemic breast cancer therapy.

Palestras:

• Room: TUMORES DE MAMA :: LOCAL - SALA GALERIA

University of Toronto

Senior Scientist, Princess Margaret Cancer Centre, University Health Network Associate Professor, Department of Medical Biophysics, University of Toronto Chair, Genetics and Epigenetics Program, Princess Margaret Cancer Centre Joey and Toby Tanenbaum Brazilian Ball Chair in Prostate Cancer Research, University of Toronto Dr. He received his B.S. degree in physics from Beijing Normal University in the year of 2003, and then transitioned to the genomics and noncoding RNA fields for his Ph.D training in the Institute of Biophysics, Chinese Academy of Sciences. He received his postdoctoral training in cancer genomics and epigenomics at Dana-Farber Cancer Institute. After completing his postdoctoral training in 2011, Dr. He worked as an instructor at Harvard Medical School and was recruited as a scientist at the Princess Margaret Cancer Centre in 2013. The He laboratory applies a variety of genomic, epigenomic experimental and computational approaches to elucidate the functional role of epigenetic regulation in cancer development, progression and drug response/resistance, with a special focus on the interplay between epigenetic regulator and noncoding RNA under stress conditions such as hypoxia. Dr. He’s work in the fields of noncoding RNA and epigenetics has resulted in ~50 peer-reviewed publications in high-impact journals including Nature, Cell, Nature Genetics, Nature Methods and Nature Communications.

Palestras:

• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Hospital italiano -Buenos Aires

General Urologist, former resident and Chief Resident at Hospital Italiano de Buenos Aires in 2002-2003. Live in La Plata where I practice general Urology in public and private centers and also I am Assistant Professor of Urology in La Plata National University. Became Health Applied Statistics Specialist at Buenos Aires University in 2007 and Clinic Investigation Master in 2017, acting since 2006 as Asociated Medical Doctor in the Urology Department at Hospita Italiano de Buenos Aires acting as Scientific and Statistics Advisor. Currently reviewer of the International Brazilian Journal of Urology and the Argentinian Journal of Urology. Author of various indexed publications and member of the American Urological Association, Sociedad Argentina de Urología and the Latin American Renal Cancer Group. For this last group I´m coordinating a study about Active Surveillance in Renal Cancer.

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Instituto de Biomedicina de Sevilla

Dr. Javier Martin Broto studied Medicine between 1982 and 1988 at the School of Medicine of Zaragoza and obtained the official title of Specialist in Medical Oncology at Son Dureta Hospital, Palma de Mallorca in 1994. From 1994 to 2014 he treated sarcomas in this hospital, which ultimately became a Center of Reference for Sarcoma. Since september of 2014, he moved to the University Hospital of Virgen Del Rocio in Sevilla to coordinate the multidisciplinary sarcoma team.

Palestras:

• Room: SARCOMAS E TUMORES ÓSSEOS :: LOCAL - R39/40

SLAGO

Dr Jorge Osvaldo Gallardo Escobar is a specialist in medical oncology, as well as in internal medicine, both of which are certified by the National Autonomous Certification Corporation of Medical Specialties (CONACEM). He graduated as a physician at the University of Concepción. He did his fellowship at the Clinical Hospital of the University of Chile, thereafter he continued his studies in Germany at the Clinical Hospital of Free University of Berlin, and later, at various university hospitals in the United States. Dr Gallardo is a leading oncologist in Chile; he has conducted studies with the purpose of improving the treatment of various types of cancers. His most relevant achievements are first positive trial in gallbladder cancer and the concept that this disease had to be studied as a different disease. He is the president of the Chilean Foundation for the Development of Oncology, with this Institution he created SLAGO a meeting that began 12 years ago. He is especially noted for his work in the evaluation and treatment of gastrointestinal cancers. He currently works as a specialist in oncology at the Clínica Indisa.

Palestras:

• Room: TUMORES COLORRETAIS :: LOCAL - BALLROOM 1
• Room: TUMORES DO APARELHO DIGESTIVO ALTO :: LOCAL - R30/31

University of Texas

Prof. Livia Schiavinato Eberlin was born and raised in Campinas, São Paulo, Brazil. As an undergrad, she visited the Aston Laboratory at Purdue University to also pursue undergraduate research in MS. She received her B.S. in Chemistry from UNICAMP in 2007 and then moved to the USA in 2008 to start a PhD program in Analytical Chemistry at Purdue University. During her PhD, Livia developed and applied ambient ionization MS imaging to human cancer diagnosis. In recognition of her innovative PhD work, Livia received many awards including the Nobel Laureate Signature Award from the American Chemical Society. In 2012, she started her postdoctoral work at Stanford University where she continued to develop MS technology for biomedical research. During that time, she received the L’Oréal for Women in Science Fellowship, a K99 pathway to independence award from the NIH/NCI, and was listed in the Forbes 30 under 30 list in Science and Healthcare. In 2016, Livia started her independent career as an Assistant Professor in the Chemistry Department at the University of Texas at Austin.

Palestras:

• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO

MEDx CARE

Innovation and excellence define me, I m the promoter of the digital hospital in frontier countries. I take pride in being a challenger of the status quo. I am an ambidextrous thinker with good abilities to match strategic with operational thinking, technical with managerial knowledge, as well as rational with intuitive insights. People describe me as entrepreneurial and energizing, for the enthusiasm l exhibit towards situations that require new knowledge and innovative thinking.

Palestras:

• Room: INOVAÇÕES E TECNOLOGIAS

Mount Sinai

Paz Polak, PhD, is an assistant professor in Mount Sinai Health System. A motivated computational biologist who is interested to eliminate cancer and improving health via genomics and data analysis. Academic accomplished scientist with multiple high impact publications on mutational processes and their link to genetics ,epigenetic and exposure. His next challenge and ultimate one is to lead efforts in translating these findings to public health and industries.

Palestras:

• Room: TUMORES DE MAMA :: LOCAL - SALA GALERIA
• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO

Institut Curie

Palestras:

• Room: INSTITUT CURIE

Memorial Sloan Kettering Cancer Center

Dr Pierre Anhoury is the head of international relations for Institut Curie in Paris, France He covers international patients admission, international doctors and nurses for training and fellowships and institutional partnerships. By training he is specialized in public health and clinical oncology Before joining Institut Curie, he spent 25 years as healthcare management consultant with EY, Deloitte, IMS health, Kantar Health and Accenture. He published 2 books: Quality and Risk Management in Hospitals in 1993 and Guide for well aging in 2017 He teaches health economy, drug evaluation and health technology assessment related to cancer at ESA business school (Lebanon)

Palestras:

• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO
• Room: SARCOMAS E TUMORES ÓSSEOS :: LOCAL - R39/40
• Room: TUMORES DE MAMA :: LOCAL - SALA GALERIA
• Room: TUMORES GINECOLÓGICOS :: LOCAL - BALLROOM 3
• Room: TUMORES COLORRETAIS :: LOCAL - BALLROOM 1
• Room: ENDOSCOPIA DIGESTIVA NOS TUMORES GASTROINTESTINAIS :: LOCAL - BALLROOM 1
• Room: TUMORES DO APARELHO DIGESTIVO ALTO :: LOCAL - R30/31
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Institut Curie

Dr Dendale Rémi, Radiation Oncologist since 1995, arrived at the Institut Curie - Paris in 1997 as a specialist of breast cancer and ophthalmic tumor radiotherapy. In 2000 he was in charge of the ocular patients in the proton therapy center. Chief of service of the Proton Therapy Center in 2008, he has supported the modernization of the Proton Therapy Center in 2010. Since 2016, he is Deputy Director of the institut curie proton therapy center. This centre is equiped with a proton accelerator and three treatment rooms and has treated more than 9,500 patients since 1991.

Palestras:

• Room: INSTITUT CURIE

Memorial Sloan Kettering Cancer Center

Sarat Chandarlapaty is an Associate Professor of Medicine at Memorial Sloan Kettering Cancer Center in New York. He has devoted the past 12 years to breast cancer research. During postdoctoral fellowship in the laboratory of Dr. Neal Rosen, Sarat studied regulation of PI3K/AKT signaling, leading to the understanding that cancer cells have activated feedback regulation of oncogenic networks that ultimately promote adaptive drug resistance. In 2012, Sarat joined the faculty at MSKCC and has focused on understanding the basis for resistance to endocrine therapies. His laboratory helped identify and characterize mutation in ESR1 as the dominant mechanism of clinical resistance to aromatase inhibitors. Following on the heels of this work, he has helped lead the development of ER antagonists as a means of overcoming ER mutants. The laboratory’s ongoing work is to understand the molecular basis for hormone and growth factor dysregulation of breast cancer progression and drug resistance.

Palestras:

• Room: TUMORES DE MAMA :: LOCAL - SALA GALERIA
• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO
• Room: SARCOMAS E TUMORES ÓSSEOS :: LOCAL - R39/40
• Room: TUMORES COLORRETAIS :: LOCAL - BALLROOM 1
• Room: ENDOSCOPIA DIGESTIVA NOS TUMORES GASTROINTESTINAIS :: LOCAL - BALLROOM 1
• Room: TUMORES DO APARELHO DIGESTIVO ALTO :: LOCAL - R30/31
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

City Of Hope Comprehensive Cancer Center

Dr. Sumanta Kumar Pal, is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 80 manuscripts in peer-reviewed journals. He has presented his work in multiple international meetings.

Palestras:

• Room: AVANÇOS DO CARCINOMA RENAL
• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO
• Room: TUMORES UROLÓGICOS :: LOCAL - SALA GALERIA

Institut Curie

Dra. Sylvie Bonvalot has specialized in surgery of sarcoma and complex tumors for around twenty years. After working as Chief resident in digestive surgery, she worked at Gustave Roussy from 1994 to 2015, before joining Institut Curie. She has treated over 4,000 patients suffering from sarcoma or complex tumors of the abdomen and soft tissues of the limbs.

Palestras:

• Room: INSTITUT CURIE
• Room: SARCOMAS E TUMORES ÓSSEOS :: LOCAL - R39/40

University of Ottawa

Scientist at the Children’s Hospital of Eastern Ontario Research Institute (CHEO RI), and Assistant Professor of Biochemistry, Microbiology and Immunology at the University of Ottawa, Ottawa, Canada. My training is in virology, innate immune responses, cell biology, and oncology. I received my B.Sc. (2000) in Biochemistry from University Laval in Quebec City, Canada, and my Ph.D. (2007) in Medical Science from the University of Calgary, Canada. During my Ph.D. research, I studied the virology and the oncolytic potencies of reovirus, vesicular stomatitis virus, herpes simplex virus and myxoma virus against brain cancers. From 2007 to 2013 I pursued post-doctoral work at McGill University studying mRNA translational control and the mammalian target of rapamycin (mTOR) signaling pathway, linking both viral immunity and oncology research. My current research in Ottawa focuses on exploiting translation initiation factors and downstream effectors of mTOR complex 1 to modulate innate immune responses to oncolytic viruses, and to augment the anti-proliferative efficacies of cancer therapeutics. I am a member of the Canadian Oncolytic Virus Consortium, a group of scientists from across Canada that seeks to understand, improve, and develop oncolytic viral immunotherapies for the treatment of cancer.

Palestras:

• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO

Princess Margaret Cancer Centre

Prof. Tracy Mcgaha, is a Scientist and Associate Professor at Princess Margaret Cancer Center, Department of Immunology-University of Toronto.

Palestras:

Children's Hospital of Eastern Ontario Research Institute

Dr. Tyson Graber received his B.Sc. and Ph.D. From the University of Ottawa, Canada where he specialized in non-canonical mechanisms of translation control, uncovering RNA binding proteins that regulate Internal Ribosome Entry Site-mediated translation during the cellular stress response. Dr. Graber then pursued postdoctoral training in the molecular mechanisms of memory at the Montreal Neurological Institute from 2010 until 2014. There, he uncovered a unique translational control mechanism that mediates synaptic plasticity which is dysregulated in Fragile X Syndrome. Since returning to Ottawa, Dr. Graber has applied his knowledge of translational control to understanding how viruses and bacteria usurp host ribosomes. He has established expertise in ribosome profiling, a “big data” method of surveying the efficiency of translation across all mRNAs in a cell and a way to understand how non-canonical translation mechanisms function in various disease states.

Palestras:

• Room: INSIGHTS IN TRANSLATIONAL CANCER RESEARCH :: LOCAL - TEATRO